Scott R, et al. - In patients with type 2 diabetes and mild renal insufficiency, the researchers compared the efficacy and safety of the DPP-4 inhibitor sitagliptin with the SGLT-2 inhibitor dapagliflozin. For this investigation, patients with HbA1c 7.0 to 9.5% (53 to ≤80 mmol/mol) and eGFR 60 to <90 mL/min/1.73m² on metformin (≥1500 mg/day) ± sulfonylurea were randomized to sitagliptin 100 mg (N=307) or dapagliflozin 5 mg titrated to 10 mg (N=306) once-daily for 24 weeks. They found that mild renal insufficiency and inadequate glycemic control on metformin ± sulfonylurea, sitagliptin treatment resulted in greater improvement in glycemic control compared with dapagliflozin and was generally well-tolerated in patients with type 2 diabetes.